0
Lung Cancer |

Personalized Peptide Vaccination for Refractory Small Cell Lung Cancer

Yasuhiro Terazaki*, MD; Takashi Mine, MD; Yoshiyama Koichi, MD; Masahiro Mitsuoka, MD; Shinzo Takamori, MD; Akira Yamada, MD; Tetsuro Sasada, MD; Kyogo Itho, MD; Kazuo Shirouzu, MD
Author and Funding Information

Department of Surgery, Kurume University School of Medicine, Kurume, Japan


Chest. 2012;142(4_MeetingAbstracts):619A. doi:10.1378/chest.1386628
Text Size: A A A
Published online

Abstract

SESSION TYPE: Lung Cancer III

PRESENTED ON: Tuesday, October 23, 2012 at 02:45 PM - 04:15 PM

PURPOSE: Since the prognosis of small cell lung cancer (SCLC) remains poor, development of new therapeutic approaches, including immunotherapies, would be desirable. In the current study, to evaluate immunological responses in refractory SCLC patients, we conducted a small scale phase II clinical trial of personalized peptide vaccination (PPV), in which vaccine antigens are selected based on pre-existing host immunity.

METHODS: Ten refractory SCLC patients, who had failed to respond to chemo- and/or chemoradiotherapies(median number of regimens, 2.5; median duration,20.5 months), were enrolled. A maximum of four human leukocyte antigen (HLA)-matched peptides showing higher antigenspecific humoral responses were subcutaneously administered (weekly for six consecutive weeks and then bi-weekly thereafter).

RESULTS: PPV was terminated before the 3rd administration in four patients because of rapid disease progression, whereas the remaining six patients completed at least one cycle (six times) of vaccinations. Peptide-specific immunological boosting was observed in all of the six patients at the end of the first cycle of vaccinations, with their survival time of 25, 24.5 (alive), 10(alive), 9.5, 6.5, and 6 months. Number of previous chemotherapy regimens and frequency of CD3+CD26+ cells in peripheral blood were potentially prognostic in the vaccinated patients(hazard ratio [HR] = 2.540, 95% confidence interval [CI] = 1.188- 5.431, P = 0.016; HR = 0.941, 95% CI = 0.878-1.008, P = 0.084; respectively).

CONCLUSIONS: Based on the feasible immune responses in refractory SCLC patients who received at least one cycle (six times) of vaccinations, PPV could be recommended for a next stage of larger- scale, prospective clinical trials.

CLINICAL IMPLICATIONS: PPV might be one of the new treatment of small cell lung cancer.

DISCLOSURE: The following authors have nothing to disclose: Yasuhiro Terazaki, Takashi Mine, Yoshiyama Koichi, Masahiro Mitsuoka, Shinzo Takamori, Akira Yamada, Tetsuro Sasada, Kyogo Itho, Kazuo Shirouzu

No Product/Research Disclosure Information

Department of Surgery, Kurume University School of Medicine, Kurume, Japan

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543